STOCKHOLM – November 8, 2017 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, has added new members to its advisory board for DESUTO, a Eurostar sponsored research program within digital pathology. Professor Junya Fukuoka of the Department of Pathology in Nagasaki and Professor Fredrik Pontén of Uppsala University have both joined the prominent group of experts.
Fukuoka is a lung cancer specialist, creator of the Nagasaki NET digital pathology network and is heavily involved in the advanced education of pathologists in Japan. Pontén is a board-certified specialist of anatomical pathology, a skin cancer expert and Clinical Director of the Human Protein Atlas project.
The DESUTO advisory board now includes experts in a variety of disciplines:
· Prof. Anil Parwani, prostate cancer expert
· Dr. Jeroen van der Laak, expert in deep learning based analysis of pathology images
· Dr. Dan Ciresan, pioneer in deep learning technology
· Prof. Junya Fukuoka, expert in lung diseases
· Prof. Fredrik Pontén, skin cancer expert
“We are very pleased that we have established an advisory board with a wealth of expertise and knowledge. This is of utmost importance to ensure development of products with outstanding clinical value,” said Anita Tollstadius, CEO, ContextVision.
This week, an advisory board meeting was held in Paris to discuss the key issues in the DESUTO research program and details regarding the upcoming prostate cancer product.
“It is our intention to take a strong position within the digital pathology market and having access to such a strong global advisory board is vital. We appreciate the excellent collaboration of this team and the great collegial atmosphere. The meeting gave us a lot of valuable input for the next steps”, said Tollstadius.
The DESUTO project has received funding from the Eurostars-2 Joint Program with co-funding from the European Union’s Horizon 2020 research and innovation program. The research program will continue for one year with the first product for prostate cancer ready for commercial use in Europe by the end of 2018.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit http://www.contextvision.com